OmniAb, Inc. (NASDAQ:OABI - Get Free Report) shares rose 2.8% during mid-day trading on Friday . The company traded as high as $3.69 and last traded at $3.67. Approximately 58,374 shares traded hands during trading, a decline of 88% from the average daily volume of 502,255 shares. The stock had previously closed at $3.57.
Wall Street Analyst Weigh In
A number of research analysts have recently commented on OABI shares. HC Wainwright reissued a "buy" rating and set a $11.00 target price on shares of OmniAb in a research report on Thursday, November 14th. Benchmark reiterated a "buy" rating and issued a $8.00 price objective on shares of OmniAb in a report on Thursday, November 14th.
Check Out Our Latest Stock Report on OABI
OmniAb Trading Up 0.6 %
The company has a market capitalization of $506.97 million, a price-to-earnings ratio of -5.79 and a beta of -0.14. The stock has a 50-day simple moving average of $3.95 and a 200-day simple moving average of $4.13.
Institutional Investors Weigh In On OmniAb
Hedge funds and other institutional investors have recently modified their holdings of the stock. Palumbo Wealth Management LLC lifted its holdings in OmniAb by 12.5% during the 3rd quarter. Palumbo Wealth Management LLC now owns 24,640 shares of the company's stock worth $104,000 after buying an additional 2,744 shares during the last quarter. Sei Investments Co. raised its position in shares of OmniAb by 11.0% during the 2nd quarter. Sei Investments Co. now owns 29,024 shares of the company's stock valued at $109,000 after acquiring an additional 2,888 shares in the last quarter. China Universal Asset Management Co. Ltd. raised its position in shares of OmniAb by 64.5% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 22,727 shares of the company's stock valued at $96,000 after acquiring an additional 8,909 shares in the last quarter. CWC Advisors LLC. bought a new position in OmniAb during the third quarter worth $54,000. Finally, FMR LLC boosted its holdings in OmniAb by 10.6% in the third quarter. FMR LLC now owns 138,813 shares of the company's stock worth $587,000 after purchasing an additional 13,324 shares during the period. Institutional investors own 72.08% of the company's stock.
About OmniAb
(
Get Free Report)
OmniAb, Inc, a biotechnology company, engages in the discovery and provision of therapeutic antibody discovery technologies in the United States. The company's technology platform creates and screens diverse antibody repertoires and identify optimal antibodies for partners' drug development efforts.
Recommended Stories
Before you consider OmniAb, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and OmniAb wasn't on the list.
While OmniAb currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Click the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
